Jump to main content
Jump to site search

Issue 1, 2019
Previous Article Next Article

NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor

Author affiliations

Abstract

Nephrotic syndrome with idiopathic membranous nephropathy as a major contributor, is characterized by proteinuria, hypoalbuminemia and oedema. Diagnosis is based on renal biopsy and the condition is treated using immunosuppressive drugs; however nephrotic syndrome treatment efficacy varies among patients. Multi-omic urine analyses can discover new markers of nephrotic syndrome that can be used to develop personalized treatments. For proteomics, a protease inhibitor (PI) is sometimes added at sample collection to conserve proteins but its impact on urine metabolic phenotyping needs to be evaluated. Urine from controls (n = 4) and idiopathic membranous nephropathy (iMN) patients (n = 6) were collected with and without PI addition and analysed using 1H NMR spectroscopy and UPLC-MS. PI-related data features were observed in the 1H NMR spectra but their removal followed by a median fold change normalisation, eliminated the PI contribution. PI-related metabolites in UPLC-MS data had limited effect on metabolic patterns specific to iMN. When using an appropriate data processing pipeline, PI-containing urine samples are appropriate for 1H NMR and MS metabolic profiling of patients with nephrotic syndrome.

Graphical abstract: NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor

Back to tab navigation

Supplementary files

Publication details

The article was received on 13 Aug 2018, accepted on 17 Dec 2018 and first published on 09 Jan 2019


Article type: Research Article
DOI: 10.1039/C8MO00190A
Mol. Omics, 2019,15, 39-49

  •   Request permissions

    NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor

    C. L. Boulangé, I. M. Rood, J. M. Posma, J. C. Lindon, E. Holmes, J. F. M. Wetzels, J. K. J. Deegens and M. R. Kaluarachchi, Mol. Omics, 2019, 15, 39
    DOI: 10.1039/C8MO00190A

Search articles by author

Spotlight

Advertisements